explore -WSS

explore

author：fashion 2025-10-06 09:54:50 - browse：84

Peter Marks, Director of the Center for Biologics Evaluation and Research at the US Food and Drug Administration (FDA), testifies during a Senate Health, Education, Labor and Pensions Committee hearing to discuss the on-going federal response to Covid-19 on May 11, 2021 at the US Capitol in Washington, DC. — FDA's Peter Marks JIM LO SCALZO/POOL/AFP via Getty Images

WASHINGTON — The Food and Drug Administration needs dozens more reviewers if it wants its so-called Operation Warp Speed for rare disease therapies to take off, the agency’s biologics chief said Monday.

The administration launched the rare disease pilot program, dubbed START and modeled after the record race for a Covid-19 vaccine, this September. Peter Marks, head of the Center for Biologics Evaluation and Research, has spearheaded both initiatives.

“If we were really to expand this significantly, [it] would require us to get dozens of additional staff members,” Marks told listeners during a gene therapy discussion hosted by the Alliance for a Stronger FDA. “One could say ‘Oh my goodness, he’s asking for more headcount again.’ Well, if this really does reduce the time to development by 25 to 50% … it probably won’t take industry too long to do a net present value calculation to say ‘Oh, it’s worth making sure that they have their extra 20 or 30 or 40 reviewers.’”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： R.J. Reynolds sues to protect 'crisp' cigs from California flavor ban

WSS

President Biden's budget: Here's what you might have missed

Abortion pill case raises question: who can sue the FDA?

Will generative AI in health care meet the fate of IBM's Dr. Watson?

Readout Newsletter: CAR

Readout Newsletter: Blackstone Life Sciences, Merck, Bluebird Bio

First U.S. drug developed to treat liver disease MASH is approved

knowledge

explore

Wikipedia

United colonoscopy coverage change 'may cost lives,' doctors say

Covid vaccine financial winners and losers, from Pfizer to Novavax

Tori Bowie and the unacceptable rates of Black maternal death

R.J. Reynolds sues to protect 'crisp' cigs from California flavor ban

Malaria cases in Florida and Texas: Here’s what you need to know

The Readout: Lenmeldy, GLP

Wildfire smoke exposes gaps in outdoor worker protections

Merck drug for rare lung condition set for approval in U.S.

Trump demands the U.S. pay no more for drugs than other countries … again

Covid vaccine financial winners and losers, from Pfizer to Novavax

leisure time

President Biden's budget: Here's what you might have missed

Supreme Court mifepristone arguments center on docs' right to sue

R.J. Reynolds sues to protect 'crisp' cigs from California flavor ban

Study says nonprofit hospitals fall short in charity care spending

Vertex Pharmaceuticals may move headquarters in Boston

Readout Newsletter: CAR

hotspot

knowledge

hotspot

focus